CTLA4 and melanoma: To prove our observation, SubMap analysis was employed to compare the expression patterns of the Cluster1/Cluster2 subtypes with previously published datasets of melanoma patients who accepted anti-CTLA-4 and/or anti-PD-1 therapies.